Lale Tokgözoğlu: Significant CV Benefit of Lowering LDL to 44 mg/dL in Diabetes
Lale Tokgözoğlu, Professor of Cardiology at Hacettepe University, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“Our analysis from the Vesalius trial showed significant benefit of lowering LDL to a median of 44 mg/dL in diabetics presented at ACC26.”
Title: Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes Results From the VESALIUS-CV Trial
Authors: Nicholas A. Marston, Erin A. Bohula, Ajay K. Bhatia, Gaetano M. De Ferrari, Lawrence A. Leiter, Jose C. Nicolau, Jeong-Gun Park, Sabina A. Murphy, Emileigh Walsh, Lyrica Liu, Subodh Verma, Naveed Sattar, Stephen J. Nicholls, Jose Lopez-Sendon, Ioanna Gouni-Berthold, Lale Tokgozoglu, Ron Blankstein, Marcoli Cyrille, Gabriel Paiva da Silva Lima, Robert P. Giugliano, Marc S. Sabatine
Read the Full Article on Jama
More posts featuring Lale Tokgözoğlu on Hemostasis Today
-
Aug 21, 2026, 15:53Gregory Lim: Nicotine Products and Cardiovascular Risk
-
Aug 21, 2026, 15:26Mariusz Kruk: Plaque-Directed Intervention for the Prevention of Myocardial Infarction
-
Aug 21, 2026, 15:17Leveraging Data to Drive Sustainable Care for Haemophilia and Haemoglobinopathies – NNHF
-
Aug 21, 2026, 15:04Sex Differences in Platelet Function in Type 2 Diabetes – Seminars in Thrombosis and Hemostasis
-
Aug 21, 2026, 15:04Parth Parmar: RBC Morphology – A Practical Guide to Blood Smear Interpretation
-
Aug 21, 2026, 14:32Kenneth Nollet: Building the Future of Transfusion Laboratory Science
-
Aug 21, 2026, 14:14Tareq Abadl: A Positive Antibody Screen is Not The Diagnosis
-
Aug 21, 2026, 14:08Katrina Snow։ Transfusion Trends and Quality Improvement in Sickle Cell Disease
-
Aug 21, 2026, 14:00Rucha Patil: The Power of Point-of-Care Testing in Hemostasis